Project Grant K22CA282361
Award Date 7/1/26
Completion Date 6/30/29
Dollars Obligated $195K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30314, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a Project Grant of $531,825 under the Cancer Biology Research program (CFDA 93.396) effective August 1, 2025, with completion targeted for July 31, 2030. This research initiative focuses on understanding the molecular mechanisms of castration sensitivity in prostate epithelium, with the ultimate goal of improving therapeutic responses to androgen-deprivation therapy...
- Federal Grant Award Summary Duke University received a $2.89 million Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded August 1, 2025, with completion scheduled for July 31, 2029. This research project, titled "Understanding and Targeting Epigenetic Regulation of Immune Evasion in Prostate Cancer," will investigate how epigenetic mechanisms—specifically through the TNRC18 protein—regulate immune evasion in...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $658,423 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026, through June 30, 2031, to conduct fundamental research on therapeutic targeting of PI3K gamma-positive tumor-associated macrophages (TAMs) in metastatic castration-resistant prostate cancer (MCRPC). The research aims to develop innovative therapeutics that reduce health disparities...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $419,036 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded September 10, 2025, with completion targeted for March 9, 2028. This award supports biomedical research training and workforce development focused on investigating sex hormone signaling mechanisms in hepatocellular carcinoma (HCC) treatment. The project delivers...
- Federal Project Grant Award Summary The National Cancer Institute awarded The Johns Hopkins University a $354,658 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective August 1, 2025 through July 31, 2030. This award supports fundamental research investigating subclonal P27 (CDKN1B) loss as a driver of aggressive prostate cancer, with particular focus on understanding health disparities affecting Black or African American males who experience prostate cancer mortality...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $148,626 through the Cancer Research Manpower program (CFDA 93.398) to the University of Pennsylvania, effective December 1, 2025 through April 30, 2028. This Project Grant supports research training and workforce development focused on elucidating the role of N6-methyladenosine (m6A) modifications on messenger RNA (mRNA) during adaptive stress responses in prostate cancer. The research addresses a critical gap in...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of California, Los Angeles a $404,972 Project Grant effective August 1, 2025, through July 31, 2027, under the Cancer Treatment Research program (CFDA 93.395). This award supports fundamental and applied research investigating mechanisms of radiopharmaceutical therapy (RPT) resistance in metastatic castration-resistant prostate cancer. The research will evaluate how the ectonucleotidase enzyme ENPP1...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $100,228 Project Grant under the Cancer Research Manpower program (CFDA 93.398) effective December 1, 2026, through May 31, 2029. This award supports research training and workforce development in cancer biology aligned with the National Cancer Program's priorities. The funded project investigates the molecular mechanisms of MYC-driven transcriptional reprogramming in prostate cancer...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $497,972 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, with a completion date of March 31, 2031. The award supports research to develop and evaluate EZH2 (Enhancer of Zeste Homolog 2)-targeting therapeutics for advanced prostate cancer, particularly castration-resistant prostate cancer (CRPC). The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Arizona a $588,677 Project Grant under the Cancer Biology Research program (CFDA 93.396) for the period July 1, 2026, through June 30, 2031. This award funds fundamental research investigating hypoxia-mediated centrosome instability as a driver of prostate cancer progression. The research objectives center on determining whether oxygen-dependent centrosome instability contributes to prostate cancer...